![Jason O’Byrne](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jason O’Byrne
Director of Finance/CFO at
OLEMA PHARMACEUTICALS, INC.
Net worth: 412 766 $ as of 2026-08-30
Profile
Mr. Jason V.
O’Byrne is a Chief Financial & Accounting Officer at Olema Pharmaceuticals, Inc. Mr. O’Byrne was previously employed as a Chief Financial Officer & Executive Vice President by Vir Biotechnology, Inc., a Chief Financial & Accounting Officer by Caribou Biosciences, Inc., a Senior Vice President-Finance by Audentes Therapeutics, Inc., a Regional Controller by General Chemical Corp., and a Regional Head-Commercial Finance APAC by Genentech, Inc. He received his undergraduate degree from the University of British Columbia and an MBA from The Leonard N Stern School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-03-30 | 37,730 ( 0.02% ) | 412 766 $ | 2026-08-30 |
Jason O’Byrne active positions
| Companies | Position | Start |
|---|---|---|
| OLEMA PHARMACEUTICALS, INC. | Director of Finance/CFO | 2026-08-10 |
Former positions of Jason O’Byrne
| Companies | Position | End |
|---|---|---|
| VIR BIOTECHNOLOGY, INC. | Director of Finance/CFO | 2026-08-02 |
| CARIBOU BIOSCIENCES, INC. | Director of Finance/CFO | 2024-09-26 |
| AUDENTES THERAPEUTICS, INC. | Director of Finance/CFO | 2021-01-31 |
General Chemical Corp.
 General Chemical Corp. Industrial SpecialtiesProcess Industries Manufactures and supplies metal lubricant products | Corporate Officer/Principal | 2004-12-31 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | - |
Training of Jason O’Byrne
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
66
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Caribou Biosciences, Inc.
 Caribou Biosciences, Inc. BiotechnologyHealth Technology Develops technology-based solutions for cellular engineering and analysis | Health Technology |
University of British Columbia
 University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
General Chemical Corp.
General Chemical Corp. Industrial SpecialtiesProcess Industries Manufactures and supplies metal lubricant products | Process Industries |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes gene therapy products for patients with serious rare diseases | Health Technology |
The Leonard N Stern School of Business
 The Leonard N Stern School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vir Biotechnology, Inc.
 Vir Biotechnology, Inc. BiotechnologyHealth Technology Develops cures and treatments drug for viral & bacterial diseases | Health Technology |
Olema Pharmaceuticals, Inc.
 Olema Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for the treatment & prevention of estrogen receptor positive breast cancer | Health Technology |
- Stock Market
- Insiders
- Jason O’Byrne
